Phase 2 Colorectal Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given their signed agreement to take part in the trial.
• People who are 18 years of age or older at the time of signing consent.
• People who have a confirmed diagnosis of colorectal cancer (adenocarcinoma) that cannot be surgically removed and/or has spread to other parts of the body, with known results for RAS, BRAF, and MSI tumour markers.
• People who agree to take part in an additional research program that runs alongside the trial.
• People who have not previously received any treatment for their cancer in a palliative (non-curative) setting — meaning this would be their first treatment of this kind.
• People who are largely able to care for themselves and carry out light activities (a standard fitness measure doctors use, scored 0 or 1 out of 5).
• People whose blood counts, liver function, and kidney function meet specific healthy ranges as assessed by blood tests (confirm exact values with the trial site).
• People whose blood calcium and phosphate levels are within the normal range.
• People who are willing and able to follow the trial schedule, including attending appointments and completing all required visits.
• People of childbearing potential, or those with partners of childbearing potential, who agree to use highly effective contraception during treatment and for a specified period afterwards, and female participants who have a negative pregnancy test within 7 days before starting treatment.

Who may not be able to join:

• People whose colorectal cancer is considered curable.
• People who have previously been treated with a type of drug that targets FGFR (a specific protein involved in cancer growth).
• People who have another active cancer, other than certain treated skin cancers or treated cervical pre-cancers, unless they received curative treatment and have been cancer-free for at least 5 years (the trial sponsor reviews these cases individually).
• People who have cancer that has spread to the brain or the lining of the brain/spinal cord that is either untreated or currently causing symptoms.
• People with a history of, or current, significant disorders affecting calcium and phosphate balance in the body unrelated to their tumour, or abnormal mineral deposits in soft tissues or organs.
• People who are currently receiving other cancer treatments such as immunotherapy, chemotherapy, or hormone-based cancer therapy not described in this trial (palliative radiotherapy for symptom relief only may be acceptable — confirm with trial site).
• People with significant liver scarring (cirrhosis) of a certain severity, or cirrhosis of any level combined with a history of brain complications from liver disease or significant fluid build-up in the abdomen.
• People who have a known allergy or sensitivity to any of the trial medications.
• People who have moderate or severe nerve damage causing weakness, numbness, or pain (grade 2 or higher neuropathy).
• People who have taken the herbal supplement St. John's Wort within 6 weeks before starting the trial.
• People with existing or ongoing eye conditions, including but not limited to certain retinal disorders, macular degeneration, diabetic eye disease, or previous retinal detachment.
• People who have had other serious illnesses or medical conditions within the 12 months before the trial starts.
• People with an active, uncontrolled infection.
• People with a condition where the blood's clotting system is abnormally activated throughout the body (disseminated intravascular coagulation).
• People with any other serious health condition that, in the doctor's judgement, would put them at high risk or reduce the likelihood of the trial being effective for them.
• People who have taken part in another interventional clinical trial within 28 days before enrolling, or who are currently in another interventional trial at the same time.
• People who have had major surgery within 4 weeks, extended-field radiotherapy within 4 weeks, limited-field radiotherapy within 2 weeks, or any experimental drug treatment within 4 weeks before starting the trial.
• People who are pregnant, breastfeeding, or planning to become pregnant within 6 months after finishing treatment.
• People who have previously been treated with certain immunotherapy drugs that target PD-1, PD-L1, or CTLA-4 pathways.
• People who have an active autoimmune disease or a history of autoimmune disease (such as autoimmune hepatitis, certain lung, eye, bowel, or kidney conditions, or others — confirm specifics with the trial site). Some conditions such as childhood asthma that has fully resolved may still be eligible (confirm with trial site).
• People who have a weakened immune system, or who are taking steroid medication above a certain dose, or other immune-suppressing medications within 2 weeks before starting treatment.
• People with uncontrolled HIV infection, or ongoing hepatitis B or C infection.
• People who have received a solid organ transplant.
• People with a history of a lung condition called interstitial lung disease.

Important: Always verify eligibility with the trial site directly before applying.